MedTrace Logo

Rosiglitazone and Insulin Resistance in Renally Impaired Patients

NCT00452166 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-10-02

No results posted yet for this study

Summary

30 non-diabetic, non-obese patients with stage 4 chronic kidney disease will be asked to participate in this metabolic study.

The primary aim of this study is to determine the effect of rosiglitazone on insulin resistance in non-obese patients with non-diabetic stage 4 CKD.

Secondary end points are the effects on inflammation (hsCRP), lipid profile, bone density and body composition.

Conditions

Interventions

DRUG

rosiglitazone

Sponsors & Collaborators

  • Leiden University Medical Center

    lead OTHER

Principal Investigators

  • andre gaasbeek, md · LUMC leiden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-03-31
Completion
2008-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00452166 on ClinicalTrials.gov